

Research Article

Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients

Shuichi Tatarano , **Akihiko Mitsuke**, **Takashi Sakaguchi**, **Ryosuke Matsushita**, **Satoru Inoguchi**, **Hirofumi Yoshino**, **Hiroaki Nishimura**, **Yasutoshi Yamada**, and **Hideki Enokida**

Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

Correspondence should be addressed to Shuichi Tatarano; taracho@m3.kufm.kagoshima-u.ac.jp

Received 20 February 2022; Revised 1 May 2022; Accepted 25 June 2022; Published 21 July 2022

Academic Editor: Martin Sedlacek

Copyright © 2022 Shuichi Tatarano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. We analyzed the clinical outcomes of laparoscopic adrenalectomy for pheochromocytomas in hemodialysis compared with nonhemodialysis patients. **Methods.** Fifty-seven patients (7 hemodialysis and 50 nonhemodialysis) were included in the study. We analyzed the differences in clinical parameters and outcomes between the hemodialysis patient groups and non-hemodialysis patient groups as well as identified predictors for an intraoperative hypertensive spike. **Results.** The increasing intravascular volume before surgery in hemodialysis patients made perioperative hemodynamic management safer. No significant difference in clinical parameters between the two groups was observed except for the length of hospitalization that was significantly longer in the hemodialysis patients (9 vs. 6 days, $P = 0.005$). An increase in systolic blood pressure at CO₂ insufflation was an independent predictor of a hypertensive spike with a cutoff value of 22.5 mmHg (odds ratio 1.038, 95% confidence interval 1.012–1.078). **Conclusion.** Laparoscopic adrenalectomy for pheochromocytomas in hemodialysis was safe and feasible. An increase in systolic blood pressure at CO₂ insufflation was a predictor of the intraoperative hypertensive spike. The research in this manuscript is not registered. This is a retrospective study.

1. Introduction

Pheochromocytoma is a rare endocrine disease, occurring in 0.1 to 0.6% of patients with hypertension [1, 2]. Sustained or paroxysmal hypertension is the most common sign of pheochromocytoma. Measurement of urinary and plasma catecholamines and catecholamine metabolites is typically used to diagnose pheochromocytoma. However, diagnosing a pheochromocytoma is difficult in hemodialysis (HD) patients because symptoms such as hypertension are seen commonly, while anuria results in no urine sample available for testing [3]. Furthermore, pheochromocytomas are rare in HD patients, and we found only 22 cases in the English literature. To date, no study has compared the perioperative outcomes of pheochromocytoma surgery between HD and nonhemodialysis (non-HD) patients. Here, we reported our preoperative hemodynamic management strategies and the

outcome of laparoscopic adrenalectomy for a pheochromocytoma in HD patients. We also investigated the factors predicting an intraoperative hypertensive spike in all patients with pheochromocytoma.

2. Patients and Methods

2.1. Patients. Between May 2007 and December 2020, 57 patients were admitted to our hospital for laparoscopic surgery of pheochromocytoma and were included in this retrospective study.

2.2. Preoperative Management. Preoperative antihypertensive agents were prescribed for all patients, even those who were normotensive, to prevent unpredictable intraoperative hemodynamic instability. All the patients were prescribed

doxazosin, an alpha-adrenergic receptor blockade, with an initial dosage of 2 mg per day increased to a maximum of 16 mg per day if necessary. In addition, the baseline dry weight of the HD patients was increased by 0.5–1.0 kg the day before surgery to increase intravascular volume.

2.3. Surgical Procedure. The laparoscopic surgery was performed using a transperitoneal approach according to the surgeon's preference. After induction of general anesthesia, the patient was placed in a full-plank position. The first 10 mm trocar was placed, and a 12 mmHg CO₂ pneumoperitoneum was created. The other trocars were then placed at four finger widths below the costal margin. The pneumoperitoneum was maintained at 8–10 mmHg throughout the entire procedure. The adrenal vessels were dissected and either clipped with vessel clips or sealed, and the tumor specimen was removed using an entrapment bag.

Intraoperative hypertension was controlled by intravenous administration of a vasodilator. The surgeon also paused the surgical procedure and worked with the anesthesiologist to stabilize the hemodynamic status. After removal of the pheochromocytoma, hypotension was treated with fluid and intravenous vasopressor agents as needed.

2.4. Data Analysis. We retrospectively analyzed patient characteristics in the HD and non-HD patient groups. The following clinical parameters were compared in the two groups: age, gender, body mass index (BMI), affected side, tumor size, preoperative systolic blood pressure (sBP), plasma catecholamine levels, iodine-123-metaiodobenzylguanidine (¹²³I-MIBG) scintigraphy, smoking history, and use of oral antihypertensive drugs.

We also analyzed the following operative outcomes to evaluate the safety of laparoscopic adrenalectomy: operative time, estimated blood loss (EBL), intraoperative maximum sBP, and length of hospital stay.

We defined a sudden elevation in intraoperative sBP > 180 mmHg as a hypertensive spike, emulating the criteria in our previous publication [4]. We used univariate and multivariate analyses to determine the factors that predicted a hypertensive spike. Receiver operating characteristic (ROC) curve analysis was used to determine the minimum cutoff value of each factor that predicted a hypertensive spike.

2.5. Statistical Analysis. EZR software (Saitama Medical Center, Jichi Medical University), based on R (The R Foundation for Statistical Computing, version 4.0.2) and R Commander (version 2.7-0), was used for the statistical analyses in the study [5]. The relationships between the two patient groups were analyzed using the Mann–Whitney *U* test, chi-square analysis, and Fisher's exact test. Univariate and multivariate logistic regression were used to determine the factors that predicted an intraoperative hypertensive spike. *P* values < 0.05 were considered to indicate statistical significance.

3. Results

Of the 57 patients with pheochromocytoma, seven were assigned to the HD patient group (Table 1). The median (range) for age was 61 (44–67) years, the duration of HD, 21 (5–34) years, and the dosage of preoperative doxazosin, 12 (2–16) mg per day. In Case 6, plasma catecholamine levels were within the normal range, although ¹²³I-MIBG scintigraphy showed radionuclide accumulation in the tumor.

There were 50 patients in the non-HD group. Table 2 shows a comparison of patient demographic and clinical parameters between the HD and non-HD groups. No significant difference was observed for any of the parameters in either group. As shown in Table 3, there were also no significant differences between the two groups for operative outcomes, including operative time, EBL, sBP elevation at CO₂ insufflation, and maximum intraoperative sBP. The anesthesiologist used antihypertensive and antihypotensive medications during the surgery. Examples of such drugs include phentolamine mesylate, nicardipine hydrochloride, diltiazem hydrochloride, noradrenaline, and dopamine hydrochloride. Patients requiring treatment for hypertension during the surgery were 6 of 7 (86%) in the HD group and 41 of 50 (82%) in the non-HD group (*P* = > 0.999). Patients requiring treatment for hypotension after the surgery were 1 of 7 (14%) in the HD group and 5 of 50 (10%) in the non-HD group (*P* = 0.562). All the patients with postoperative hypotension recovered on postoperative day 1. However, we found that the length of hospital stay in the HD group was significantly longer than in the non-HD group (9 vs. 6 days, *P* = 0.005). Intraoperative fluid balance was also significantly less than in the non-HD group (720 vs. 1950 mL, *P* = 0.004) (Table 3). There were no intraoperative complications, and the postoperative course was uneventful in both groups.

The univariate and multivariate analyses to identify clinical factors that predicted a hypertensive spike are shown in Table 4. Of the significant predictors identified in the univariate analysis, sBP elevation at CO₂ insufflation (odds ratio 1.038, 95% confidence interval 1.012–1.078, *P* = 0.017) was the only independent predictive factor identified in the multivariate analysis. ROC curve analysis showed that an increase of 22.5 mmHg in sBP at CO₂ insufflation had a sensitivity of 62.5% and a specificity of 83.3% (area under the ROC curve 0.754, *P* = 0.001) (Figure 1). Four patients (57%) in the HD group and 28 (56%) in the non-HD group had a hypertensive spike. This difference between the two groups was not statistically significant. Of the patients who experienced a hypertensive spike, 4 (100%) HD patients and 16 (57%) non-HD patients had an increase in sBP at CO₂ insufflation that exceeded the cutoff value used to predict a crisis (i.e., >22.5 mmHg).

4. Discussion

Pheochromocytoma is a rare catecholamine-secreting tumor that occurs in 0.1 to 0.6% of patients with hypertension [1, 2]. It is estimated that the annual incidence of pheochromocytoma is approximately 0.8 per 100,000 person-years [6].

TABLE 1: Characteristics of the hemodialysis patient with pheochromocytoma.

Case	Age	Sex	HD duration (yr)	Tumor size (mm)	Doxazosin (mg/day)	E (pg/mL)	NE (pg/mL)	DA (pg/mL)	MIBG uptake
1	59	Male	11	29	2	385	906	17	yes
2	61	Female	34	25	2	50	610	40	yes
3	61	Female	30	40	10	273	525	76	yes
4	48	Female	26	22	12	257	1328	28	yes
5	44	Female	5	47	16	395	2818	24	yes
6	64	Male	21	60	16	64	233	13	yes
7	67	Female	17	26	16	80	599	18	yes

HD, hemodialysis; E, epinephrine; NE, norepinephrine; DA, dopamine; MIBG, metaiodobenzylguanidine.

TABLE 2: Comparison of clinical parameters in the HD and non-HD patient groups.

	HD	Non-HD	P value
Number	7	50	
Age	61 (44–67)	56 (24–86)	0.948
Sex (male/female)	2/5	28/22	0.173
BMI (kg/m ²)	22.2 (19.3–28.2)	22.3 (16.2–28.7)	0.762
Side (right/left)	3/4	25/25	0.723
Tumor size (mm)	29 (22–60)	40 (15–95)	0.282
Preoperative Sbp	120 (114–208)	129 (87–170)	0.597
Epinephrine (pg/mL)	257 (50–395)	148 (15–3221)	0.563
Norepinephrine (pg/mL)	610 (233–2818)	1454 (198–8112)	0.131
Dopamine (pg/mL)	24 (13–76)	18 (5–216)	0.190
MIBG uptake (yes/no)	7/0	48/1	>0.999
Smoking (yes/no)	1/6	22/28	0.223
Antihypertensive drug (yes/no)	6/1	25/25	0.112

HD, hemodialysis; BMI, body mass index; sBP, systolic blood pressure; MIBG, metaiodobenzylguanidine.

TABLE 3: Operative outcomes in the HD and non-HD patient groups.

	HD	Non-HD	P value
Operative time (min)	213 (113–321)	159 (32–363)	0.200
EBL (mL)	50 (20–320)	20 (3–880)	0.138
Intraoperative sBP max (mmHg)	195 (131–288)	199 (114–300)	0.804
sBP elevation at CO ₂ insufflation (mmHg)	35 (0–177)	19 (0–136)	0.640
Time to sBP elevation at CO ₂ insufflation (min)	5 (3–20)	6 (1–19)	0.813
Hypertensive spike number (%)	4 of 7 (57%)	28 of 50 (56%)	>0.999
Exceeded the cutoff value of 22.5 mmHg (%)	4 of 4 (100%)	16 of 28 (57%)	0.271
Intraoperative fluid balance (mL)	720 (708–1315)	1950 (1540–2425)	0.004
Required treatment for hypertension during surgery	6 of 7 (86%)	41 of 50 (82%)	>0.999
Required treatment for hypotension after surgery	1 of 7 (14%)	5 of 50 (10%)	0.562
Hospital stays (day)	9 (7–11)	6 (3–18)	0.005

HD, hemodialysis; EBL, estimated blood loss; sBP, systolic blood pressure.

TABLE 4: Univariate and multivariate analyses of clinical factors for predicting a hypertensive spike in all the patients.

	Univariate			Multivariate		
	OR	95% CI	P value	OR	95% CI	P value
Tumor size	1.018	0.991–1.050	0.215	—	—	—
Epinephrine	1.002	1.000–1.004	0.855	—	—	—
Norepinephrine	1.000	1.000–1.001	0.086	0.999	0.995–1.001	0.468
Epinephrine + norepinephrine	1.000	1.000–1.001	0.035	1.002	0.999–1.005	0.366
Preoperative sBP	0.996	0.969–1.023	0.752	—	—	—
Operative time	1.005	0.997–1.015	0.219	—	—	—
sBP elevation at CO ₂ insufflation	1.044	1.018–1.082	0.005	1.038	1.012–1.078	0.017

OR, odds ratio; CI, confidence interval; sBP, systolic blood pressure.




FIGURE 1: ROC curve analysis of systolic blood pressure elevation during pneumoperitoneum creation predicting the hypertensive spike. The sensitivity was 62.5% and specificity was 83.3% when systolic blood pressure increased >22.5 mmHg from baseline levels.

The symptoms consist of episodic headaches, sweating, and tachycardia in approximately 50% of patients with pheochromocytoma, and when present, they are typically paroxysmal. Hypertension, the most common abnormality, occurs in more than 90% of patients and is paroxysmal in 25% to 50% of cases [7].

Pheochromocytoma in an HD patient is rare. To our knowledge, only 22 cases of pheochromocytoma in association with HD have been reported in the English literature [8–11]. The diagnosis of pheochromocytoma in HD patients can be challenging. Unfortunately, because of aneurin, only blood testing is available. Plasma catecholamine levels in HD patients is generally higher than those in normal controls, although a three-fold increase in plasma catecholamine should raise the suspicion of pheochromocytoma [3]. In imaging studies, computed tomography (CT) and magnetic resonance imaging (MRI) have similar sensitivity (93–100%) and specificity (50%). This low specificity is a major problem in both imaging techniques. In contrast, MIBG scintigraphy has superior specificity (95%–100%), although false-negative results have been reported in 10–15% of cases with pheochromocytoma [12, 13]. In our study, all seven cases had positive results for I^{123} -MIBG scintigraphy, despite a false-negative result for MIBG scintigraphy having been reported in a previous case report of an HD patient [8]. These findings suggest that it is necessary to diagnose pheochromocytoma in HD patients based on the levels of blood catecholamine or catecholamine metabolites and imaging findings such as CT, MRI, and MIBG scintigraphy.

Once a pheochromocytoma is diagnosed, all patients should undergo resection of the tumor following appropriate medical preparation. Hemodynamic instability during the surgical procedure for a pheochromocytoma with inadequate or absent preoperative antihypertensive therapy or unrecognized hypovolemia contributes to a high mortality

rate. Preoperative antihypertensive treatment is therefore recommended for patients with sustained or paroxysmal hypertension and also normotensive patients [14]. However, there is no evidence of the optimal endpoint for blood pressure. Retrospective studies suggest that the endpoint for blood pressure of less than 130/80 mmHg while seated and greater than 90 mmHg systolic while standing seems reasonable [15]. The perioperative management of HD patients is essentially the same as that used in non-HD patients [16]. However, preoperative hemodialysis may result in insufficient extracellular fluid volume, which in turn may lead to hypotension after the removal of the tumor. In some reports on the optimal adjustment of dry weight, a 1% to 3% increase in dry weight is recommended in HD patients [11, 17, 18]. Based on the findings of these reports, we approached surgery by increasing the dry weight preoperatively. Using this strategy, we encountered no significant problems with intraoperative hemodynamics in our cases.

Minimally invasive adrenalectomy is a safe procedure for the resection of pheochromocytoma [19, 20]. To date, there are only a small number of reports on laparoscopic surgery for pheochromocytoma in HD patients, and to the best of our knowledge, this is the first report to show that laparoscopic surgery for pheochromocytoma was comparable in HD and non-HD patients. However, the length of hospital stay in the HD group was longer because of the perioperative HD schedule.

Previous retrospective studies have reported that the factors that predicted severe intraoperative hypertension included preoperative preparation, catecholamine levels, intraoperative management, tumor characteristics, and the surgical approach [15, 21, 22]. Occasionally, we experience an increase in sBP shortly after the CO_2 insufflation. This phenomenon may be because of pneumoperitoneum pressure on the tumor. However, there are no reports on the correlation between pneumoperitoneum and hemodynamics in laparoscopic pheochromocytoma surgery. Only one prospective study identified tumor size as a factor that predicted an intraoperative hypertensive spike (i.e., sBP >180 mmHg) [4]. In our univariate analysis of the predictive factor for an intraoperative hypertensive spike, catecholamines and preoperative sBP were included as variables related to increased blood pressure. In addition, tumor size, operative time, and postpneumoperitoneum blood pressure increase were included in the variables considering the effects of the surgical procedure. Tumor size was not a significant predictive factor, whereas an increase in baseline sBP >22.5 mmHg at CO_2 insufflation was a strong predictor. In particular, all four dialysis patients with an intraoperative hypertensive spike had a higher increase in sBP than the cutoff value. Therefore, if sBP is elevated significantly during CO_2 insufflation, it is necessary to pay close attention to the possibility of an intraoperative hypertension spike during the surgical procedure.

This study had several limitations as it was a retrospective study carried out at a single center and included only a small number of cases due to pheochromocytoma being a rare disease. In addition, the effects of differences in the surgical procedures could not be ruled out.

5. Conclusion

Laparoscopic adrenalectomy for pheochromocytoma is feasible in both HD and non-HD patients. Increasing the intravascular volume before surgery in HD patients appeared to make perioperative management safer. However, further study is required to determine an adequate level for increasing preoperative dry weight. Our data indicate that an increase in sBP at CO₂ insufflation may be a predictive factor for a hypertensive spike during laparoscopic surgery for pheochromocytoma.

Data Availability

No data were used to support this study.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol and informed consent documents were reviewed and approved by the institutional review boards of Kagoshima University Hospital (No. 200270).

Consent

Informed consent was obtained in the form of opt-out on the website.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

Acknowledgments

The authors would like to thank all the patients who participated in this study.

References

- [1] W. F. Young, "Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism," *Reviews in Endocrine & Metabolic Disorders*, vol. 8, no. 4, pp. 309–320, 2007.
- [2] J. W. Lenders, G. Eisenhofer, M. Mannelli, and K. Pacak, "Pheochromocytoma," *The Lancet*, vol. 366, no. 9486, pp. 665–675, 2005.
- [3] M. Stumvoll, M. Radjaipour, and F. Seif, "Diagnostic considerations in pheochromocytoma and chronic hemodialysis: case report and review of the literature," *American Journal of Nephrology*, vol. 15, no. 2, pp. 147–151, 1995.
- [4] N. Rao, R. Ramachandran, N. Tandon, P. Singh, and R. Kumar, "Surgical and hemodynamic outcomes in pheochromocytoma surgery: a prospective cohort study," *Urology*, vol. 98, pp. 103–106, 2016.
- [5] Y. Kanda, "Investigation of the freely available easy-to-use software "EZ" for medical statistics," *Bone Marrow Transplantation*, vol. 48, no. 3, pp. 452–458, 2013.
- [6] C. M. Beard, S. G. Aheps, L. T. Kurland, J. A. Carney, and J. T. Lie, "Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo," *Clin Proc*, vol. 58, no. 12, pp. 802–804, 1983.
- [7] E. L. Bravo, "Pheochromocytoma: new concepts and future trends," *Kidney International*, vol. 40, no. 3, pp. 544–556, 1991.
- [8] M. Morioka, S. Yuihama, T. Nakajima et al., "Incidentally discovered pheochromocytoma in long-term hemodialysis patients," *International Journal of Urology*, vol. 9, no. 12, pp. 700–703, 2002.
- [9] T. Nomura, M. Yamasaki, F. Satoh, Y. Nomura, and H. Mimata, "Source of plasma adrenomedullin in a patient with pheochromocytoma receiving hemodialysis," *International Journal of Urology*, vol. 13, no. 4, pp. 427–430, 2006.
- [10] N. Ozawa, T. Okamura, K. Koyama et al., "Usefulness of F-18 FDG-PET in a long-term hemodialysis patient with renal cell carcinoma and pheochromocytoma," *Annals of Nuclear Medicine*, vol. 21, no. 4, pp. 239–243, 2007.
- [11] H. Suzuki, M. Abe, K. Tahira et al., "Successful treatment of pheochromocytoma in a patient with hemodialysis: a case report and review of the literature," *Renal Failure*, vol. 35, no. 10, pp. 1429–1433, 2013.
- [12] K. Pacak, W. M. Linehan, G. Eisenhofer, M. M. Walther, and D. S. Goldstein, "Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma," *Annals of Internal Medicine*, vol. 134, no. 4, pp. 315–329, 2001.
- [13] A. P. G. Van Gils, T. H. M. Falke, A. R. Van Erkel et al., "MR imaging and MIBG scintigraphy of pheochromocytomas and extra-adrenal functioning paragangliomas," *RadioGraphics*, vol. 11, no. 1, pp. 37–57, 1991.
- [14] J. W. M. Lenders, Q. Y. Duh, G. Eisenhofer et al., "Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline," *Journal of Clinical Endocrinology and Metabolism*, vol. 99, no. 6, pp. 1915–1942, 2014.
- [15] K. Pacak, "Preoperative management of the pheochromocytoma patient," *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 11, pp. 4069–4079, 2007.
- [16] J. A. Godfrey, O. B. Rickman, A. W. Williams, G. B. Thompson, and W. F. Young, "Pheochromocytoma in a patient with end-stage renal disease," *Mayo Clinic Proceedings*, vol. 76, no. 9, pp. 953–957, 2001.
- [17] L. Sollazzi, V. Perilli, M. A. Crea et al., "Anesthetic management of pheochromocytoma in a long term hemodialysed patient," *Acta Anaesthesiologica Belgica*, vol. 45, no. 1, pp. 13–17, 1994.
- [18] T. Yamamoto, K. Iizima, and T. Mizuguchi, "Anesthesia for a patient with pheochromocytoma associated with chronic renal failure," *Masui*, vol. 38, no. 6, pp. 805–808, 1989.
- [19] J. Sprung, J. F. O'Hara, I. S. Gill, B. Abdelmalak, A. Sarnaik, and E. L. Bravo, "Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma," *Urology*, vol. 55, no. 3, pp. 339–343, 2000.
- [20] S. Aliyev, K. Karabulut, O. Agcaoglu et al., "Robotic versus laparoscopic adrenalectomy for pheochromocytoma," *Annals of Surgical Oncology*, vol. 20, no. 13, pp. 4190–4194, 2013.
- [21] A. M. Kazaryan, N. S. Kuznetsov, A. M. Shulutko, D. G. Beltsevich, and B. Edwin, "Evaluation of endoscopic and traditional open approaches to pheochromocytoma," *Surgical Endoscopy*, vol. 18, no. 6, pp. 937–941, 2004.
- [22] T. N. Weingarten, J. P. Cata, J. F. O'Hara et al., "Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma," *Urology*, vol. 76, no. 2, 2010.